<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">Achondroplasia</z:e> is the most common genetic form of human <z:hpo ids='HP_0003510'>dwarfism</z:hpo>, for which there is presently no effective therapy </plain></SENT>
<SENT sid="1" pm="."><plain>C-type natriuretic <z:chebi fb="7" ids="16670">peptide</z:chebi> (CNP) is a newly identified molecule that regulates endochondral bone growth through GC-B, a subtype of particulate guanylyl cyclase </plain></SENT>
<SENT sid="2" pm="."><plain>Here we show that targeted overexpression of CNP in chondrocytes counteracts <z:hpo ids='HP_0003510'>dwarfism</z:hpo> in a mouse model of <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> with activated fibroblast growth factor receptor 3 (FGFR-3) in the cartilage </plain></SENT>
<SENT sid="3" pm="."><plain>CNP prevented the shortening of achondroplastic bones by correcting the decreased extracellular matrix synthesis in the growth plate through inhibition of the MAPK pathway of FGF signaling </plain></SENT>
<SENT sid="4" pm="."><plain>CNP had no effect on the STAT-1 pathway of FGF signaling that mediates the decreased proliferation and the delayed differentiation of achondroplastic chondrocytes </plain></SENT>
<SENT sid="5" pm="."><plain>These results demonstrate that activation of the CNP-GC-B system in endochondral bone formation constitutes a new therapeutic strategy for human <z:e sem="disease" ids="C0001080" disease_type="Disease or Syndrome;Congenital Abnormality" abbrv="">achondroplasia</z:e> </plain></SENT>
</text></document>